Elevation Oncology (NASDAQ:ELEV) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.

Several other equities analysts have also recently issued reports on ELEV. JMP Securities restated a market outperform rating and issued a $7.00 price target on shares of Elevation Oncology in a research report on Thursday, March 7th. HC Wainwright restated a buy rating and set a $6.00 price target on shares of Elevation Oncology in a research note on Tuesday, April 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and an average price target of $7.25.

Elevation Oncology Price Performance

Shares of NASDAQ ELEV opened at $3.70 on Friday. The business has a 50-day moving average price of $4.38 and a 200 day moving average price of $2.42. The company has a debt-to-equity ratio of 0.41, a current ratio of 46.22 and a quick ratio of 46.22. Elevation Oncology has a 52-week low of $0.36 and a 52-week high of $5.89.

Elevation Oncology (NASDAQ:ELEV) last announced its earnings results on Wednesday, March 6th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Equities analysts predict that Elevation Oncology will post -0.87 EPS for the current year.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.